Search Results for: Virus

10800 interactions found:

Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
BNIP3 and BNIP3L BCL2 interacting protein 3 BCL2 interacting protein 3 like
  • TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
CASP8 and FADD caspase 8 Fas associated via death domain
  • Apoptotic cleavage of cellular proteins
  • Caspase activation via Death Receptors in the presence of ligand
  • NOD1/2 Signaling Pathway
  • TRIF-mediated programmed cell death
  • Caspase-mediated cleavage of cytoskeletal proteins
  • Regulation by c-FLIP
  • RIPK1-mediated regulated necrosis
  • CASP8 activity is inhibited
  • TNFR1-induced proapoptotic signaling
  • Regulation of TNFR1 signaling
  • CLEC7A/inflammasome pathway
  • Regulation of necroptotic cell death
  • Dimerization of procaspase-8
  • Activation, myristolyation of BID and translocation to mitochondria
  • Apoptotic execution phase
  • FasL/ CD95L signaling
  • TRAIL signaling
  • TLR3-mediated TICAM1-dependent programmed cell death
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • Caspase activation via Death Receptors in the presence of ligand
  • TRIF-mediated programmed cell death
  • Regulation by c-FLIP
  • RIPK1-mediated regulated necrosis
  • CASP8 activity is inhibited
  • TNFR1-induced proapoptotic signaling
  • Dimerization of procaspase-8
  • FasL/ CD95L signaling
  • TRAIL signaling
  • TLR3-mediated TICAM1-dependent programmed cell death
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • Bardoxolone
  • Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
CASP8 and CHUK caspase 8 component of inhibitor of nuclear factor kappa B kinase complex
  • Apoptotic cleavage of cellular proteins
  • Caspase activation via Death Receptors in the presence of ligand
  • NOD1/2 Signaling Pathway
  • TRIF-mediated programmed cell death
  • Caspase-mediated cleavage of cytoskeletal proteins
  • Regulation by c-FLIP
  • RIPK1-mediated regulated necrosis
  • CASP8 activity is inhibited
  • TNFR1-induced proapoptotic signaling
  • Regulation of TNFR1 signaling
  • CLEC7A/inflammasome pathway
  • Regulation of necroptotic cell death
  • Dimerization of procaspase-8
  • Activation, myristolyation of BID and translocation to mitochondria
  • Apoptotic execution phase
  • FasL/ CD95L signaling
  • TRAIL signaling
  • TLR3-mediated TICAM1-dependent programmed cell death
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • Activation of NF-kappaB in B cells
  • Activation of NF-kappaB in B cells
  • ER-Phagosome pathway
  • NOD1/2 Signaling Pathway
  • TICAM1, RIP1-mediated IKK complex recruitment
  • RIP-mediated NFkB activation via ZBP1
  • AKT phosphorylates targets in the cytosol
  • Downstream TCR signaling
  • FCERI mediated NF-kB activation
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • Regulation of TNFR1 signaling
  • TNFR1-induced NFkappaB signaling pathway
  • IKBKB deficiency causes SCID
  • IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
  • IkBA variant leads to EDA-ID
  • Dectin-1 mediated noncanonical NF-kB signaling
  • CLEC7A (Dectin-1) signaling
  • Constitutive Signaling by AKT1 E17K in Cancer
  • NIK - noncanonical NF-kB signaling
  • MAP3K8 (TPL2)-dependent MAPK1/3 activation
  • Interleukin-1 signaling
  • TRAF6 mediated NF-kB activation
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • IRAK1 recruits IKK complex
  • IKK complex recruitment mediated by RIP1
  • IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
  • Bardoxolone
  • Aminosalicylic Acid
  • Mesalazine
  • Sulfasalazine
  • Acetylcysteine
  • Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
  • Cocoon syndrome
CASP8 and UBC caspase 8 ubiquitin C
  • Apoptotic cleavage of cellular proteins
  • Caspase activation via Death Receptors in the presence of ligand
  • NOD1/2 Signaling Pathway
  • TRIF-mediated programmed cell death
  • Caspase-mediated cleavage of cytoskeletal proteins
  • Regulation by c-FLIP
  • RIPK1-mediated regulated necrosis
  • CASP8 activity is inhibited
  • TNFR1-induced proapoptotic signaling
  • Regulation of TNFR1 signaling
  • CLEC7A/inflammasome pathway
  • Regulation of necroptotic cell death
  • Dimerization of procaspase-8
  • Activation, myristolyation of BID and translocation to mitochondria
  • Apoptotic execution phase
  • FasL/ CD95L signaling
  • TRAIL signaling
  • TLR3-mediated TICAM1-dependent programmed cell death
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • Translesion synthesis by REV1
  • Recognition of DNA damage by PCNA-containing replication complex
  • Translesion Synthesis by POLH
  • Activation of NF-kappaB in B cells
  • ISG15 antiviral mechanism
  • Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • ER-Phagosome pathway
  • Downregulation of ERBB4 signaling
  • Spry regulation of FGF signaling
  • Downregulation of ERBB2:ERBB3 signaling
  • Budding and maturation of HIV virion
  • NOD1/2 Signaling Pathway
  • TICAM1, RIP1-mediated IKK complex recruitment
  • DDX58/IFIH1-mediated induction of interferon-alpha/beta
  • APC/C:Cdc20 mediated degradation of Cyclin B
  • Autodegradation of Cdh1 by Cdh1:APC/C
  • SCF-beta-TrCP mediated degradation of Emi1
  • APC/C:Cdc20 mediated degradation of Securin
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Cdc20:Phospho-APC/C mediated degradation of Cyclin A
  • Membrane binding and targetting of GAG proteins
  • Assembly Of The HIV Virion
  • APC-Cdc20 mediated degradation of Nek2A
  • Vpu mediated degradation of CD4
  • Vif-mediated degradation of APOBEC3G
  • EGFR downregulation
  • SCF(Skp2)-mediated degradation of p27/p21
  • Degradation of beta-catenin by the destruction complex
  • TCF dependent signaling in response to WNT
  • Downstream TCR signaling
  • NRIF signals cell death from the nucleus
  • p75NTR recruits signalling complexes
  • NF-kB is activated and signals survival
  • Regulation of activated PAK-2p34 by proteasome mediated degradation
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Activated NOTCH1 Transmits Signal to the Nucleus
  • Activated NOTCH1 Transmits Signal to the Nucleus
  • Downregulation of TGF-beta receptor signaling
  • Downregulation of TGF-beta receptor signaling
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • Downregulation of SMAD2/3:SMAD4 transcriptional activity
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • Separation of Sister Chromatids
  • Oxidative Stress Induced Senescence
  • Senescence-Associated Secretory Phenotype (SASP)
  • Oncogene Induced Senescence
  • Regulation of PLK1 Activity at G2/M Transition
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Stimuli-sensing channels
  • Constitutive Signaling by NOTCH1 HD Domain Mutants
  • FCERI mediated NF-kB activation
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • NOTCH2 Activation and Transmission of Signal to the Nucleus
  • Regulation of innate immune responses to cytosolic DNA
  • Glycogen synthesis
  • Autodegradation of the E3 ubiquitin ligase COP1
  • Deactivation of the beta-catenin transactivating complex
  • Myoclonic epilepsy of Lafora
  • ABC-family proteins mediated transport
  • Circadian Clock
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • activated TAK1 mediates p38 MAPK activation
  • JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
  • AUF1 (hnRNP D0) binds and destabilizes mRNA
  • Asymmetric localization of PCP proteins
  • Degradation of AXIN
  • Degradation of DVL
  • Regulation of FZD by ubiquitination
  • Pink/Parkin Mediated Mitophagy
  • N-glycan trimming in the ER and Calnexin/Calreticulin cycle
  • Regulation of TNFR1 signaling
  • TNFR1-induced NFkappaB signaling pathway
  • Hedgehog ligand biogenesis
  • Hh mutants that don't undergo autocatalytic processing are degraded by ERAD
  • Dectin-1 mediated noncanonical NF-kB signaling
  • CLEC7A (Dectin-1) signaling
  • Degradation of GLI1 by the proteasome
  • Degradation of GLI2 by the proteasome
  • GLI3 is processed to GLI3R by the proteasome
  • Hedgehog 'on' state
  • Hedgehog 'on' state
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • Translesion synthesis by POLK
  • Translesion synthesis by POLI
  • Termination of translesion DNA synthesis
  • Regulation of RAS by GAPs
  • TNFR2 non-canonical NF-kB pathway
  • Negative regulation of MAPK pathway
  • Regulation of necroptotic cell death
  • NIK - noncanonical NF-kB signaling
  • Defective CFTR causes cystic fibrosis
  • MAP3K8 (TPL2)-dependent MAPK1/3 activation
  • HDR through Homologous Recombination (HRR)
  • MAPK6/MAPK4 signaling
  • UCH proteinases
  • UCH proteinases
  • Josephin domain DUBs
  • Ub-specific processing proteases
  • Ovarian tumor domain proteases
  • Metalloprotease DUBs
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Processing of DNA double-strand break ends
  • DNA Damage Recognition in GG-NER
  • Formation of Incision Complex in GG-NER
  • Gap-filling DNA repair synthesis and ligation in GG-NER
  • Dual Incision in GG-NER
  • Formation of TC-NER Pre-Incision Complex
  • Transcription-Coupled Nucleotide Excision Repair (TC-NER)
  • Dual incision in TC-NER
  • Gap-filling DNA repair synthesis and ligation in TC-NER
  • Fanconi Anemia Pathway
  • Regulation of TP53 Activity through Phosphorylation
  • Regulation of TP53 Degradation
  • Regulation of TP53 Activity through Methylation
  • Negative regulation of MET activity
  • CDT1 association with the CDC6:ORC:origin complex
  • Orc1 removal from chromatin
  • CDK-mediated phosphorylation and removal of Cdc6
  • Cyclin D associated events in G1
  • G2/M Checkpoints
  • Stabilization of p53
  • Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
  • Ubiquitin-dependent degradation of Cyclin D
  • PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • FBXL7 down-regulates AURKA during mitotic entry and in early mitosis
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • Downregulation of ERBB2 signaling
  • Synthesis of active ubiquitin: roles of E1 and E2 enzymes
  • Synthesis of active ubiquitin: roles of E1 and E2 enzymes
  • E3 ubiquitin ligases ubiquitinate target proteins
  • InlB-mediated entry of Listeria monocytogenes into host cell
  • InlB-mediated entry of Listeria monocytogenes into host cell
  • InlA-mediated entry of Listeria monocytogenes into host cells
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • Regulation of RUNX2 expression and activity
  • Regulation of RUNX2 expression and activity
  • Regulation of RUNX3 expression and activity
  • Regulation of PTEN localization
  • Regulation of PTEN stability and activity
  • Neddylation
  • ER Quality Control Compartment (ERQC)
  • Regulation of expression of SLITs and ROBOs
  • Regulation of expression of SLITs and ROBOs
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • TICAM1-dependent activation of IRF3/IRF7
  • TICAM1,TRAF6-dependent induction of TAK1 complex
  • Interleukin-1 signaling
  • Peroxisomal protein import
  • Peroxisomal protein import
  • Regulation of signaling by CBL
  • Endosomal Sorting Complex Required For Transport (ESCRT)
  • Iron uptake and transport
  • Negative regulators of DDX58/IFIH1 signaling
  • Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
  • IRAK1 recruits IKK complex
  • IKK complex recruitment mediated by RIP1
  • IRAK2 mediated activation of TAK1 complex
  • TRAF6-mediated induction of TAK1 complex within TLR4 complex
  • Negative regulation of NOTCH4 signaling
  • Chaperone Mediated Autophagy
  • Late endosomal microautophagy
  • Prevention of phagosomal-lysosomal fusion
  • Modulation by Mtb of host immune system
  • Alpha-protein kinase 1 signaling pathway
  • Aggrephagy
  • Aggrephagy
  • Pexophagy
  • TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling
  • IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
  • IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation
  • Amyloid fiber formation
  • Antigen processing: Ubiquitination & Proteasome degradation
  • Bardoxolone
  • N-Formylmethionine
  • Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
CASP8 and EIF2AK2 caspase 8 eukaryotic translation initiation factor 2 alpha kinase 2
  • Apoptotic cleavage of cellular proteins
  • Caspase activation via Death Receptors in the presence of ligand
  • NOD1/2 Signaling Pathway
  • TRIF-mediated programmed cell death
  • Caspase-mediated cleavage of cytoskeletal proteins
  • Regulation by c-FLIP
  • RIPK1-mediated regulated necrosis
  • CASP8 activity is inhibited
  • TNFR1-induced proapoptotic signaling
  • Regulation of TNFR1 signaling
  • CLEC7A/inflammasome pathway
  • Regulation of necroptotic cell death
  • Dimerization of procaspase-8
  • Activation, myristolyation of BID and translocation to mitochondria
  • Apoptotic execution phase
  • FasL/ CD95L signaling
  • TRAIL signaling
  • TLR3-mediated TICAM1-dependent programmed cell death
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • ISG15 antiviral mechanism
  • Inhibition of PKR
  • Bardoxolone
  • Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
CASP8 and MAP3K14 caspase 8 mitogen-activated protein kinase kinase kinase 14
  • Apoptotic cleavage of cellular proteins
  • Caspase activation via Death Receptors in the presence of ligand
  • NOD1/2 Signaling Pathway
  • TRIF-mediated programmed cell death
  • Caspase-mediated cleavage of cytoskeletal proteins
  • Regulation by c-FLIP
  • RIPK1-mediated regulated necrosis
  • CASP8 activity is inhibited
  • TNFR1-induced proapoptotic signaling
  • Regulation of TNFR1 signaling
  • CLEC7A/inflammasome pathway
  • Regulation of necroptotic cell death
  • Dimerization of procaspase-8
  • Activation, myristolyation of BID and translocation to mitochondria
  • Apoptotic execution phase
  • FasL/ CD95L signaling
  • TRAIL signaling
  • TLR3-mediated TICAM1-dependent programmed cell death
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • CD28 dependent PI3K/Akt signaling
  • Dectin-1 mediated noncanonical NF-kB signaling
  • TNFR2 non-canonical NF-kB pathway
  • NIK - noncanonical NF-kB signaling
  • TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway
  • Bardoxolone
  • Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
CASP8 and IKBKG caspase 8 inhibitor of nuclear factor kappa B kinase regulatory subunit gamma
  • Apoptotic cleavage of cellular proteins
  • Caspase activation via Death Receptors in the presence of ligand
  • NOD1/2 Signaling Pathway
  • TRIF-mediated programmed cell death
  • Caspase-mediated cleavage of cytoskeletal proteins
  • Regulation by c-FLIP
  • RIPK1-mediated regulated necrosis
  • CASP8 activity is inhibited
  • TNFR1-induced proapoptotic signaling
  • Regulation of TNFR1 signaling
  • CLEC7A/inflammasome pathway
  • Regulation of necroptotic cell death
  • Dimerization of procaspase-8
  • Activation, myristolyation of BID and translocation to mitochondria
  • Apoptotic execution phase
  • FasL/ CD95L signaling
  • TRAIL signaling
  • TLR3-mediated TICAM1-dependent programmed cell death
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • Activation of NF-kappaB in B cells
  • Activation of NF-kappaB in B cells
  • ER-Phagosome pathway
  • NOD1/2 Signaling Pathway
  • TICAM1, RIP1-mediated IKK complex recruitment
  • RIP-mediated NFkB activation via ZBP1
  • Downstream TCR signaling
  • FCERI mediated NF-kB activation
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • activated TAK1 mediates p38 MAPK activation
  • JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
  • SUMOylation of immune response proteins
  • Regulation of TNFR1 signaling
  • TNFR1-induced NFkappaB signaling pathway
  • IKBKB deficiency causes SCID
  • IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
  • IkBA variant leads to EDA-ID
  • CLEC7A (Dectin-1) signaling
  • MAP3K8 (TPL2)-dependent MAPK1/3 activation
  • Ub-specific processing proteases
  • Ovarian tumor domain proteases
  • Interleukin-1 signaling
  • TRAF6 mediated NF-kB activation
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • IRAK1 recruits IKK complex
  • IKK complex recruitment mediated by RIP1
  • IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
  • Bardoxolone
  • AGRO100
  • Tarenflurbil
  • Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
  • Ectodermal dysplasia associated immunodeficiency (EDA-ID), including the following two diseases: NF-kappa-B essential modulator (NEMO) defect; Inhibitor of kappa-B (I-kappa-B) defect
  • Incontinentia pigmenti
  • Osteoporosis, lymphedema, anhydrotic ectodermal dysplasia with immunodeficiency (OLEDAID); Ectodermal dysplasia, anhidrotic, with immunodeficiency, osteopetrosis, and lymphedema
CASP8 and FYN caspase 8 FYN proto-oncogene, Src family tyrosine kinase
  • Apoptotic cleavage of cellular proteins
  • Caspase activation via Death Receptors in the presence of ligand
  • NOD1/2 Signaling Pathway
  • TRIF-mediated programmed cell death
  • Caspase-mediated cleavage of cytoskeletal proteins
  • Regulation by c-FLIP
  • RIPK1-mediated regulated necrosis
  • CASP8 activity is inhibited
  • TNFR1-induced proapoptotic signaling
  • Regulation of TNFR1 signaling
  • CLEC7A/inflammasome pathway
  • Regulation of necroptotic cell death
  • Dimerization of procaspase-8
  • Activation, myristolyation of BID and translocation to mitochondria
  • Apoptotic execution phase
  • FasL/ CD95L signaling
  • TRAIL signaling
  • TLR3-mediated TICAM1-dependent programmed cell death
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • GPVI-mediated activation cascade
  • Signaling by ERBB2
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Nef and signal transduction
  • Cell surface interactions at the vascular wall
  • FCGR activation
  • PECAM1 interactions
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • DAP12 signaling
  • EPH-Ephrin signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Nephrin family interactions
  • Nephrin family interactions
  • NCAM signaling for neurite out-growth
  • NCAM signaling for neurite out-growth
  • CD28 co-stimulation
  • CD28 dependent PI3K/Akt signaling
  • CD28 dependent Vav1 pathway
  • CTLA4 inhibitory signaling
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • Ephrin signaling
  • Ephrin signaling
  • EPH-ephrin mediated repulsion of cells
  • Sema3A PAK dependent Axon repulsion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • CRMPs in Sema3A signaling
  • CRMPs in Sema3A signaling
  • VEGFA-VEGFR2 Pathway
  • Dectin-2 family
  • CD209 (DC-SIGN) signaling
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Platelet Adhesion to exposed collagen
  • Reelin signalling pathway
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • FLT3 Signaling
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated phagocytosis
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Bardoxolone
  • Dasatinib
  • 1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane
  • Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
CASP8 and IKBKB caspase 8 inhibitor of nuclear factor kappa B kinase subunit beta
  • Apoptotic cleavage of cellular proteins
  • Caspase activation via Death Receptors in the presence of ligand
  • NOD1/2 Signaling Pathway
  • TRIF-mediated programmed cell death
  • Caspase-mediated cleavage of cytoskeletal proteins
  • Regulation by c-FLIP
  • RIPK1-mediated regulated necrosis
  • CASP8 activity is inhibited
  • TNFR1-induced proapoptotic signaling
  • Regulation of TNFR1 signaling
  • CLEC7A/inflammasome pathway
  • Regulation of necroptotic cell death
  • Dimerization of procaspase-8
  • Activation, myristolyation of BID and translocation to mitochondria
  • Apoptotic execution phase
  • FasL/ CD95L signaling
  • TRAIL signaling
  • TLR3-mediated TICAM1-dependent programmed cell death
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • Activation of NF-kappaB in B cells
  • Activation of NF-kappaB in B cells
  • ER-Phagosome pathway
  • NOD1/2 Signaling Pathway
  • TICAM1, RIP1-mediated IKK complex recruitment
  • RIP-mediated NFkB activation via ZBP1
  • Downstream TCR signaling
  • p75NTR recruits signalling complexes
  • NF-kB is activated and signals survival
  • FCERI mediated NF-kB activation
  • TAK1 activates NFkB by phosphorylation and activation of IKKs complex
  • Regulation of TNFR1 signaling
  • TNFR1-induced NFkappaB signaling pathway
  • IKBKB deficiency causes SCID
  • IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
  • IkBA variant leads to EDA-ID
  • CLEC7A (Dectin-1) signaling
  • MAP3K8 (TPL2)-dependent MAPK1/3 activation
  • Interleukin-1 signaling
  • TRAF6 mediated NF-kB activation
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • IRAK1 recruits IKK complex
  • IKK complex recruitment mediated by RIP1
  • IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation
  • Bardoxolone
  • Mesalazine
  • Sulfasalazine
  • Acetylsalicylic acid
  • Auranofin
  • Arsenic trioxide
  • MLN0415
  • Acetylcysteine
  • Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
CAV1 and SRC caveolin 1 SRC proto-oncogene, non-receptor tyrosine kinase
  • Triglyceride catabolism
  • eNOS activation
  • NOSTRIN mediated eNOS trafficking
  • Basigin interactions
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • VEGFR2 mediated vascular permeability
  • Extra-nuclear estrogen signaling
  • FOXO-mediated transcription of cell cycle genes
  • Signaling by ERBB2
  • Nuclear signaling by ERBB4
  • Downregulation of ERBB4 signaling
  • PIP3 activates AKT signaling
  • GAB1 signalosome
  • Downstream signal transduction
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Integrin signaling
  • GRB2:SOS provides linkage to MAPK signaling for Integrins
  • p130Cas linkage to MAPK signaling for integrins
  • G alpha (s) signalling events
  • G alpha (i) signalling events
  • G alpha (i) signalling events
  • DCC mediated attractive signaling
  • DCC mediated attractive signaling
  • Netrin mediated repulsion signals
  • Regulation of commissural axon pathfinding by SLIT and ROBO
  • RAF activation
  • MAP2K and MAPK activation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates PTK2 signaling
  • InlA-mediated entry of Listeria monocytogenes into host cells
  • Regulation of RUNX1 Expression and Activity
  • RUNX2 regulates osteoblast differentiation
  • Regulation of RUNX3 expression and activity
  • Extra-nuclear estrogen signaling
  • Activated NTRK2 signals through FYN
  • Activated NTRK3 signals through PI3K
  • Activated NTRK3 signals through PI3K
  • Long-term potentiation
  • Signaling downstream of RAS mutants
  • Dasatinib
  • RU84687
  • RU79256
  • N6-Benzyl Adenosine-5'-Diphosphate
  • RU85493
  • RU78262
  • Phosphonotyrosine
  • Malonic acid
  • RU83876
  • RU90395
  • RU79072
  • RU78783
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • PASBN
  • RU82129
  • PAS219
  • DPI59
  • RU82197
  • Phenylphosphate
  • RU78300
  • RU79073
  • RU82209
  • ISO24
  • RU85053
  • RU78299
  • Oxalic Acid
  • RU78191
  • Citric Acid
  • RU81843
  • 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
  • Purvalanol A
  • XL228
  • Bosutinib
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
  • 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
  • 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
  • N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
  • (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
  • Ponatinib
  • Nintedanib
  • Congenital generalized lipodystrophy (CGL)
CAV1 and INSR caveolin 1 insulin receptor
  • Triglyceride catabolism
  • eNOS activation
  • NOSTRIN mediated eNOS trafficking
  • Basigin interactions
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • VEGFR2 mediated vascular permeability
  • Extra-nuclear estrogen signaling
  • FOXO-mediated transcription of cell cycle genes
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • IRS activation
  • Signal attenuation
  • Insulin receptor signalling cascade
  • Signaling by Insulin receptor
  • Insulin receptor recycling
  • Insulin Human
  • Insulin Lispro
  • Insulin Glargine
  • Insulin Pork
  • Mecasermin
  • Insulin Aspart
  • Insulin Detemir
  • Insulin Glulisine
  • Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate
  • NN344
  • AT1391
  • [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
  • Chromic chloride
  • Insulin Degludec
  • Brigatinib
  • Congenital generalized lipodystrophy (CGL)
  • Rabson-Mendenhall syndrome
  • Leprechaunism ; Donohue syndrome
CAV1 and DAG1 caveolin 1 dystroglycan 1
  • Triglyceride catabolism
  • eNOS activation
  • NOSTRIN mediated eNOS trafficking
  • Basigin interactions
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • VEGFR2 mediated vascular permeability
  • Extra-nuclear estrogen signaling
  • FOXO-mediated transcription of cell cycle genes
  • Non-integrin membrane-ECM interactions
  • ECM proteoglycans
  • ECM proteoglycans
  • Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3
  • Defective POMT2 causes MDDGA2, MDDGB2 and MDDGC2
  • Defective POMT1 causes MDDGA1, MDDGB1 and MDDGC1
  • O-linked glycosylation
  • Regulation of expression of SLITs and ROBOs
  • EGR2 and SOX10-mediated initiation of Schwann cell myelination
  • Congenital generalized lipodystrophy (CGL)
  • Limb-girdle muscular dystrophy (LGMD)
CAV1 and CD40 caveolin 1 CD40 molecule
  • Triglyceride catabolism
  • eNOS activation
  • NOSTRIN mediated eNOS trafficking
  • Basigin interactions
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • VEGFR2 mediated vascular permeability
  • Extra-nuclear estrogen signaling
  • FOXO-mediated transcription of cell cycle genes
  • Congenital generalized lipodystrophy (CGL)
CAV1 and RAC1 caveolin 1 Rac family small GTPase 1
  • Triglyceride catabolism
  • eNOS activation
  • NOSTRIN mediated eNOS trafficking
  • Basigin interactions
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • VEGFR2 mediated vascular permeability
  • Extra-nuclear estrogen signaling
  • FOXO-mediated transcription of cell cycle genes
  • GPVI-mediated activation cascade
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Nef and signal transduction
  • NRAGE signals death through JNK
  • Rho GTPase cycle
  • Regulation of actin dynamics for phagocytic cup formation
  • Regulation of actin dynamics for phagocytic cup formation
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • FCERI mediated MAPK activation
  • DSCAM interactions
  • CD28 dependent Vav1 pathway
  • EPHB-mediated forward signaling
  • Ephrin signaling
  • EPH-ephrin mediated repulsion of cells
  • Sema3A PAK dependent Axon repulsion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • PCP/CE pathway
  • Sema4D mediated inhibition of cell attachment and migration
  • DCC mediated attractive signaling
  • DCC mediated attractive signaling
  • Activation of RAC1
  • Inactivation of CDC42 and RAC1
  • VEGFA-VEGFR2 Pathway
  • Signal transduction by L1
  • VEGFR2 mediated vascular permeability
  • RHO GTPases activate PKNs
  • RHO GTPases activate CIT
  • RHO GTPases activate CIT
  • RHO GTPases activate KTN1
  • RHO GTPases activate IQGAPs
  • RHO GTPases activate PAKs
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate Formins
  • RHO GTPases Activate Formins
  • RHO GTPases Activate NADPH Oxidases
  • MAPK6/MAPK4 signaling
  • Neutrophil degranulation
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases
  • MET activates RAP1 and RAC1
  • NTRK2 activates RAC1
  • Activated NTRK2 signals through CDK5
  • Activation of RAC1 downstream of NMDARs
  • FCGR3A-mediated phagocytosis
  • FCGR3A-mediated phagocytosis
  • WNT5:FZD7-mediated leishmania damping
  • Factors involved in megakaryocyte development and platelet production
  • Dextromethorphan
  • Azathioprine
  • Guanosine-5'-Diphosphate
  • Congenital generalized lipodystrophy (CGL)
CAV1 and FLNA caveolin 1 filamin A
  • Triglyceride catabolism
  • eNOS activation
  • NOSTRIN mediated eNOS trafficking
  • Basigin interactions
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • VEGFR2 mediated vascular permeability
  • Extra-nuclear estrogen signaling
  • FOXO-mediated transcription of cell cycle genes
  • Platelet degranulation
  • GP1b-IX-V activation signalling
  • Cell-extracellular matrix interactions
  • RHO GTPases activate PAKs
  • OAS antiviral response
  • Artenimol
  • Congenital generalized lipodystrophy (CGL)
  • Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS)
  • Fronto-Otopalatodigital Osteodysplasia, including: Otopalatodigital syndrome, type I; Otopalatodigital syndrome, type II; Melnick-Needles syndrome; Frontometaphyseal dysplasia
  • Periventricular nodular heterotopia (PVNH)
  • FG syndrome (FGS); Opitz-Kaveggia syndrome
CAV1 and CAV2 caveolin 1 caveolin 2
  • Triglyceride catabolism
  • eNOS activation
  • NOSTRIN mediated eNOS trafficking
  • Basigin interactions
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • VEGFR2 mediated vascular permeability
  • Extra-nuclear estrogen signaling
  • FOXO-mediated transcription of cell cycle genes
  • Extra-nuclear estrogen signaling
  • Congenital generalized lipodystrophy (CGL)
CAV1 and EGFR caveolin 1 epidermal growth factor receptor
  • Triglyceride catabolism
  • eNOS activation
  • NOSTRIN mediated eNOS trafficking
  • Basigin interactions
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • VEGFR2 mediated vascular permeability
  • Extra-nuclear estrogen signaling
  • FOXO-mediated transcription of cell cycle genes
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Signaling by ERBB4
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • Signaling by EGFR
  • GRB2 events in EGFR signaling
  • GAB1 signalosome
  • SHC1 events in EGFR signaling
  • EGFR downregulation
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • EGFR interacts with phospholipase C-gamma
  • EGFR Transactivation by Gastrin
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signal transduction by L1
  • Constitutive Signaling by EGFRvIII
  • Inhibition of Signaling by Overexpressed EGFR
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • PTK6 promotes HIF1A stabilization
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Extra-nuclear estrogen signaling
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • HCMV Early Events
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Alvocidib
  • IGN311
  • Matuzumab
  • Vandetanib
  • Rindopepimut
  • Canertinib
  • Pelitinib
  • Varlitinib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
  • Osimertinib
  • Necitumumab
  • Depatuxizumab mafodotin
  • Icotinib
  • Neratinib
  • Zalutumumab
  • Brigatinib
  • Olmutinib
  • Congenital generalized lipodystrophy (CGL)
  • Choriocarcinoma
  • Gastric cancer
  • Bladder cancer
  • Oral cancer
  • Glioma
  • Laryngeal cancer
  • Cervical cancer
  • Esophageal cancer
CAV1 and FYN caveolin 1 FYN proto-oncogene, Src family tyrosine kinase
  • Triglyceride catabolism
  • eNOS activation
  • NOSTRIN mediated eNOS trafficking
  • Basigin interactions
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • VEGFR2 mediated vascular permeability
  • Extra-nuclear estrogen signaling
  • FOXO-mediated transcription of cell cycle genes
  • GPVI-mediated activation cascade
  • Signaling by ERBB2
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Nef and signal transduction
  • Cell surface interactions at the vascular wall
  • FCGR activation
  • PECAM1 interactions
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • DAP12 signaling
  • EPH-Ephrin signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Nephrin family interactions
  • Nephrin family interactions
  • NCAM signaling for neurite out-growth
  • NCAM signaling for neurite out-growth
  • CD28 co-stimulation
  • CD28 dependent PI3K/Akt signaling
  • CD28 dependent Vav1 pathway
  • CTLA4 inhibitory signaling
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • Ephrin signaling
  • Ephrin signaling
  • EPH-ephrin mediated repulsion of cells
  • Sema3A PAK dependent Axon repulsion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • CRMPs in Sema3A signaling
  • CRMPs in Sema3A signaling
  • VEGFA-VEGFR2 Pathway
  • Dectin-2 family
  • CD209 (DC-SIGN) signaling
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Platelet Adhesion to exposed collagen
  • Reelin signalling pathway
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • FLT3 Signaling
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated phagocytosis
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Dasatinib
  • 1-Methoxy-2-[2-(2-Methoxy-Ethoxy]-Ethane
  • Congenital generalized lipodystrophy (CGL)
CAV2 and EGFR caveolin 2 epidermal growth factor receptor
  • Extra-nuclear estrogen signaling
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Signaling by ERBB4
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • Signaling by EGFR
  • GRB2 events in EGFR signaling
  • GAB1 signalosome
  • SHC1 events in EGFR signaling
  • EGFR downregulation
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • EGFR interacts with phospholipase C-gamma
  • EGFR Transactivation by Gastrin
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signal transduction by L1
  • Constitutive Signaling by EGFRvIII
  • Inhibition of Signaling by Overexpressed EGFR
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • PTK6 promotes HIF1A stabilization
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Extra-nuclear estrogen signaling
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • HCMV Early Events
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Alvocidib
  • IGN311
  • Matuzumab
  • Vandetanib
  • Rindopepimut
  • Canertinib
  • Pelitinib
  • Varlitinib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
  • Osimertinib
  • Necitumumab
  • Depatuxizumab mafodotin
  • Icotinib
  • Neratinib
  • Zalutumumab
  • Brigatinib
  • Olmutinib
  • Choriocarcinoma
  • Gastric cancer
  • Bladder cancer
  • Oral cancer
  • Glioma
  • Laryngeal cancer
  • Cervical cancer
  • Esophageal cancer
CAV2 and SRC caveolin 2 SRC proto-oncogene, non-receptor tyrosine kinase
  • Extra-nuclear estrogen signaling
  • Signaling by ERBB2
  • Nuclear signaling by ERBB4
  • Downregulation of ERBB4 signaling
  • PIP3 activates AKT signaling
  • GAB1 signalosome
  • Downstream signal transduction
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Integrin signaling
  • GRB2:SOS provides linkage to MAPK signaling for Integrins
  • p130Cas linkage to MAPK signaling for integrins
  • G alpha (s) signalling events
  • G alpha (i) signalling events
  • G alpha (i) signalling events
  • DCC mediated attractive signaling
  • DCC mediated attractive signaling
  • Netrin mediated repulsion signals
  • Regulation of commissural axon pathfinding by SLIT and ROBO
  • RAF activation
  • MAP2K and MAPK activation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • MET activates PTK2 signaling
  • InlA-mediated entry of Listeria monocytogenes into host cells
  • Regulation of RUNX1 Expression and Activity
  • RUNX2 regulates osteoblast differentiation
  • Regulation of RUNX3 expression and activity
  • Extra-nuclear estrogen signaling
  • Activated NTRK2 signals through FYN
  • Activated NTRK3 signals through PI3K
  • Activated NTRK3 signals through PI3K
  • Long-term potentiation
  • Signaling downstream of RAS mutants
  • Dasatinib
  • RU84687
  • RU79256
  • N6-Benzyl Adenosine-5'-Diphosphate
  • RU85493
  • RU78262
  • Phosphonotyrosine
  • Malonic acid
  • RU83876
  • RU90395
  • RU79072
  • RU78783
  • 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
  • PASBN
  • RU82129
  • PAS219
  • DPI59
  • RU82197
  • Phenylphosphate
  • RU78300
  • RU79073
  • RU82209
  • ISO24
  • RU85053
  • RU78299
  • Oxalic Acid
  • RU78191
  • Citric Acid
  • RU81843
  • 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
  • Purvalanol A
  • XL228
  • Bosutinib
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
  • 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
  • 1-cyclopentyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
  • 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
  • N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
  • (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
  • Ponatinib
  • Nintedanib

Page 5 out of 540 pages